Type 3 diabetes

From Wikipedia, the free encyclopedia

Type 3 diabetes (i.e., T3D) has been suggested to be an alternate name for a certain form of Alzheimer's disease (i.e., AD) in individuals with type 2 diabetes (i.e., T2D).[1] AD accounts for 60% to 80% of all dementias. It currently afflicts 55 million individuals and is expected to afflict 139 million by the year 2050.[2] There are two forms of AD. Early-onset Alzheimer's disease (i.e., EOAD) generally afflicts individuals between 45 to 65 years of age and accounts for 5% to 6% of all AD cases. About 10-20 % of EOAD cases are due to inheriting a defective gene (see Early onset AD). The remaining cases of EOAD are associated with various risk factors such as head injuries, cardiovascular diseases, chronic schizophrenia, the Down syndrome, and lifestyle features such as poor diets, smoking, alcohol use, and sedentary lifestyles.[2][3] The other form of AD is termed late onset AD (i.e., LOAD). It is typically diagnosed in individuals more than 64 years old. LOAD is caused by neuroinflammation in certain areas of the brain which result in the formation of excessive phosphorylation of proteins such as the Tau protein and the accumulation of plaques (i.e., misfolded and clumped protein fragments of the amyloid beta protein i.e., Aβ) in brain neurons. The formation of these and other proteins can cause the dysfunction of brain neurons.[4] It is the form of AD associated with T2D: LOAD is almost twice as common in individuals who have T2D. A study done in the USA found that there were 71,550 deaths between 1999 and 2019 among individuals who had both LOAD and T2D. Because the brain tissues of individuals with LOAD are abnormally resistant to insulin's stimulation of neurons, some studies have termed LOAD in individuals with T2D as T3D. This is based on the idea that T2D causes LOAD.[1][4][5][6] T2D is a disease in which the tissues of individuals are insulin resistant and their β-pancreatic cells are functionally impaired. It afflicts about 10% of the world's population. T2D that afflicts brain neurons is suggested to be the cause for T3D.[1][2][7][5] The insulin resistance that develops in brain neurons deprives these neurons of the glucose needed for survival. This leads to progressively increasing neuronal death, memory impairment, cognitive decline, and, ultimately, the dementia diagnosed as LOAD.[1] T2D includes 90% of all diabetes cases, occurs most often in adults who are obese and do not exercise, and requires insulin and/or dietary treatments.[8] There are two other types of diabetes. Type 1 diabetes is due to the death of the insulin-producing beta cells in the pancreas caused by an autoimmune system's attack and killing of the insulin-producing pancreatic beta cells (i.e., β-cells). It most commonly develops in childhood and adolescence, accounts for 5-10% of all diabetes cases, and involves the production of autoantibodies that kill the insulin-producing beta cells in 90% to 95% of these patients. It is treated with insulin therapy.[9] Type 3c diabetes (i.e., T3c, also termed pancreatogenic diabetes) involves 1-9% of all diabetic cases. It is caused by injuries to the pancreas due to, e.g., pancreatitis, pancreatic ductal adenocarcinoma (pancreatic ductal carcinoma is the most common form of pancreatic cancer), cystic fibrosis, brocalculous pancreatic disease, and surgical removal of the pancreas.[10]

AD is distinguished from other forms of dementia. Vascular dementia (i.e., VD) is the second most common form of dementias. It is caused by the damaging of key blood vessel due to stroke, atherosclerosis, and various other cardiovascular diseases.[11][12] Other forms of dementia are regarded as a subtype of "Alzheimer's disease-related dementias" (i.e., ADRDs). ADRDs consists of 4 other forms of dementia: VA, Lewy body dementia (which is subclassified as dementias with Lewy bodies), Parkinson's disease dementia, and frontotemporal dementia.[13] Gestational diabetes (i.e., GD) is a form of diabetes that develops in females during but then resolves after their pregnancy. There is a 10-fold increased risk that GD-afflicted females will develop T2D compared to those without GD and the offspring of individuals with GD also have an elevated risk for developing T2D.[14] GD is in generally not considered in studies of T2D and dementias. Since many studies on T2D did not clearly define LOAD and may have included some patients with EODM, the following sections will use the term DM for the studied patients.

Studies examining the role of T2D in causing AD

Genetic studies

A study of 500 patients with Parkinson's disease dementia, 400 patients with AD, and 500 with neither disease examined 32 genetic variationss in their CDC123, CDKAL1, CDKN2B, FTO, Zinc finger protein 3, HHEX, IGF2BP2, KCNJ11, KCNQ1, SLC30A8, and TCF7L2 genes. The study did not find any significant associations between these variants with the risk of developing AD or the severity of the cognitive impairments in patients with Parkinson's disease.[15] A more recent study examined the associations between polygenic risk scores (i.e., PRSs) for T2D in 29,139 adults (mean age 55) followed for 20–23 years. (PRSs are numerical estimates of an individual's genetic susceptibility to a specific disease or trait, calculated by analyzing genetic variations in their genome.) The study found higher PRSs were associated with the development of VA but not AD.[16] Another study examined genome-wide association studies (i.e., GWAS) in T2D in 29 139 adults (mean age 55) followed for 20–23 years. The study found higher PRSs were associated with the development of VA but not AD.[16] A third study of 33,136 idividuals (mean age 72.5 years old) from southern China compared the PRSs of individuals with various forms of non-T2D-unassociated dementia to individuals with T2D-associated dementia. It examined the closeness of the genomic variants of individuals without dementia to those of individuals with various forms of dementia. It found a highly significant relationship between the PRSs in T2D to those with VD but not to AD or other forms of dementia.<https://www.genome.gov/Health/Genomics-and-Medicine/Polygenic-risk-scores. The study suggested that the genetic variants in Chinese individuals with T2D contribute to their development of VD but not AD or other forms of dementia.[17] Similar results occurred in a study which examined 658,582 veterans in the United States of America Department of Veterans Affairs enrolled in the Million Veteran Program (see Joel Kupersmith#Veterans Advocacy). Another study used Mendelian randomization methods to analyze 8 publications that included 88,905 up to 788,989 individuals all of whom were of European ancestry. Mendelian randomization uses the properties of genetic variations (usually single nucleotide polymorphisms) in germline cells. Finding a set of genetic variants are associated with an outcome adds strength to the conclusion that the exposure has a causal effect on the outcome. This method is most commonly implemented using the instrumental variables estimation. The study found no evidence for a causal relationship between genetically predicted T2D and genetically predicted AD.[18][19] These studies agree in finding a genetic relationship between T2D and VA but not between T2D and AD.[15][16][17][18]

T2D inhibitor studies

Pioglitazone is a PPAR-gamma agonist that is effective in treating T2D. Two phase III clinical trials evaluated the safety and efficacy of pioglitazone in treating mild cognitive impairments in patients with early-onset AD. Both trials were terminated because the drug did not show sufficient efficacy.[20][21] Another study examined the effects of various drugs used to treat T2D in 1,094,761 patients that for the first-time were diagnosed with AD. The drugs included insulin, metformin (also termed Glucophage), dipeptidyl-peptidase-4 inhibitors, sodium-glucose cotransporter-2 inhibitors, sulfonylureas, thiazolidinediones, and GLP-1 receptor agonists (i.e., albiglutide, dulaglutide, exenatide, liraglutide, lixisenatide, and semaglutide). The study found that only one of these drugs, semaglutide (also termed Ozempic, Rybelsus, and Wegovy): a) caused a lower risk of developing AD and b) significantly lowered AD-related medication prescriptions in patients who developed AD. This study suggests that inhibiting T2D in general does not suppress AD, that the inhibitory action of semaglutide was not caused by its anti-AD actions, and supports future studies to determine the cause for semaglutide's favorable actions in treating AD.[21] Semaglutide inhibits activation of the Glucagon-like peptide-1 receptor. It has been successfully used to inhibit the progression of Type 2 diabetes as well as to treat obesity, hypertension, and cardiovascular diseases. Studies have suggested that it may be useful for treating AD.[22][23] However, two randomized, double-blinded studies of 3808 adults aged 55–85 years-old with AD evaluated the efficacy and safety of oral semaglutide compared to a placebo in treating AD. (The study's definition of AD included detection of certain amyloid proteins in the brain by positron emission tomography or cerebrospinal fluid). Adverse events during treatment were reported in 1,729 (i.e., 91.2%) of 1896 participants receiving semaglutide and 1613 (84.8%) of 1,902 receiving a placebo. There was one fatality in the semaglutide-treated and four fatalities in the placebo group. Thes study's results failed to support the conclusion that semaglutide reduced the risk of AD.[24] https://www.biospace.com/press-releases/novo-nordisk-a-s-evoke-phase-3-trials-did-not-demonstrate-a-statistically-significant-reduction-in-alzheimers-disease-progression) Taken together, these studies indicate that inhibiting T2D does not inhibit the development of AD.[20][21][22][23][24]

Studies on statins as inhibitors of dementia

Many studies published before 2018 have suggested that a class of drugs, the statins (e.g., rosuvastatin), may impair cognition in patients without dementia but also may improve the cognition and inhibit the progression of AD. That is, the statins may prove useful in preventing and treating dementias including AD.[25] A recent review of 55 studies which included over 7 million patients found that: a) the statins significantly reduced the risk of developing dementia; b) their effects were greater in patients taking the statins for longer time periods (i.e., 3 years versus less than 1 year); c) the statins proved effective in reducing the development of AD, AD in individuals with T2D, and VA; and d) the statins were more effective in individuals from Asia or the Americas. The statins tested were for these effects were rosuvastatin (which had the strongest action), atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, and simvastatin. Further studies focusing on the mechanism for the inhibitory actions of the statins may reveal their mechanism of action and the relationship of this mechanism to other agents that inhibit the development and/or progression of various dementias.[26] https://www.psychologytoday.com/us/blog/in-the-public-interest/202405/type-3-diabetes-what-you-need-to-know

Conclusions

The above studies do not support the concept the T3D as a term for T2D that leads to brain neuronal death and AD. This concept is still a new one that is rejected by many experts and is not recognized by various medical groups such as the American Diabetes Association,https://www.webmd.com/diabetes/alzheimers-diabetes-link, American Medical Association,https://www.psychologytoday.com/us/blog/in-the-public-interest/202405/type-3-diabetes-what-you-need-to-know, and the American Psychiatric Association.https://www.webmd.com/diabetes/alzheimers-diabetes-link

References

Related Articles

Wikiwand AI